Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
F/m Emerald Life Sciences Innovation ETF (LFSC) belongs to the Life Sciences segment. SPDR S&P Pharmaceuticals ETF (XPH) is part of the US Health Care segment. LFSC's top 3 sector exposures are Health Care and Sovereign. In contrast, XPH's top sector exposures are Health Care LFSC is more expensive with a Total Expense Ratio (TER) of 0.79%, versus 0.35% for XPH. LFSC is down -3.7% year-to-date (YTD) with +$7M in YTD flows. XPH performs better with -0.63% YTD performance, and +$93M in YTD flows. Run a side-by-side ETF comparison of LFSC and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | LFSC XPH | -2.09%-3.39% | -10.37%-1.18% | -3.70%-0.63% | +60.97%+28.38% | n/a+46.04% | n/a+12.03% |
| Flows | LFSC XPH | +$7M+$17M | +$8M+$95M | +$7M+$93M | +$18M+$117M | -+$58M | -+$41M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | LFSC XPH | +22.01%+20.32% | +28.67%+23.10% | n/a+19.03% | n/a+20.28% |
| Max drawdown | LFSC XPH | -13.02%-5.97% | -19.03%-17.10% | n/a-23.45% | n/a-33.10% |
| Max drawdown duration | LFSC XPH | 90d13d | 70d140d | n/a322d | n/a1706d |
LFSC | XPH | |
Last sale 3/11/2026 at 1:30 PM | $35.01 | $55.49 |
| Previous close 03/10/2026 | $35.21 | $55.67 |
| Consolidated volume 03/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
LFSC | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
LFSC | XPH | |
|---|---|---|
| Last price | $35.01 | $55.49 |
| 1D performance | -0.57% | -0.32% |
| AuM | $95.79 M | $320.49 M |
| E/R | 0.79% | 0.35% |
LFSC | XPH | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Emerald Group | SPDR |
| Benchmark | - | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 34 | 49 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | October 31, 2024 | June 19, 2006 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Direxion partnered with Compound Insights and Vanda to explore what’s driving the evolution of active trading — and how active traders are using leveraged and inverse funds across equities, single stocks, commodities, and volatility.
